

- 22 -

The Claims Defining the Invention are as Follows

- 1 A method of treating cancer in a patient comprising administering to the patient an amount of oxaliplatin in combination with radioactively doped particle, characterised in that the two therapies when introduced into the patient have a synergistic anticancer effect.
- 2 A method according to claim 1 wherein in addition to oxaliplatin other chemotherapeutic agents are also delivered to the patient with the oxaliplatin.
- 3 A method according to claim 2 wherein an effective anticancer amount of 5-FU and or LV are administered with oxaliplatin or a oxaliplatin based therapy'
- 4 A method according to claim 2 wherein other chemotherapeutic agents that may be employed in the method include systemic chemotherapy drugs such as irinotecan or capecitabine.
- 5 A method according to anyone of the preceding claims wherein the patient is also treated with an anti-angiogenesis factor.
- 6 A method according to anyone of the preceding claims wherein the patient is also treated with other anticancer agents including antibodies targeted against a cancer cells or the blood vessels supplying the cancer cells or antibodies targeting EGF and VEGF.
- 7 A therapeutic combination of anticancer agents comprising an effectively therapeutic amount of oxaliplatin and an amount of radionuclide-doped agent suitable for SIRT to effectively treat a cancer, characterised in that the combination when administered to a patient leads to a synergistic anticancer effect that is therapeutically more efficacious that either treatment when administered alone.
- 8 A therapeutic composition according to 7 wherein oxaliplatin is combined with 5-fluorouracil and leucovorin.

- 23 -

- 9 A therapeutic composition according to 8 wherein oxaliplatin is combined with other systemic chemotherapy drugs such as irinotecan or capecitabine.
- 10 A therapeutic composition according to 8 wherein oxaliplatin is combined with an anti-angiogenesis factor.
- 5 11 A therapeutic composition according to 8 wherein oxaliplatin is combined with an anticancer agent including antibodies targeted against a cancer cells or the blood vessels supplying the cancer cells or antibodies targeting EGF and VEGF.
- 10 12 Use of effective amounts of oxaliplatin and an amount of radionuclide-doped particles suitable for SIRT to effectively treat cancer in the preparation of a medicament for the treatment of cancer.